Working… Menu
Trial record 24 of 540 for:    IFNA2 AND RBV AND IFN alfa-2


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01517308
Recruitment Status : Withdrawn (Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial)
First Posted : January 25, 2012
Last Update Posted : March 19, 2012
Information provided by (Responsible Party):
Prof. Guglielmo Borgia, Federico II University

Brief Summary:
Aim of the present study is to evaluate in a cohort of patients with genotype 2/3 chronic hepatitis C, relapsers to a previous PEG-IFN + ribavirin therapy (alpha-2a or alpha-2b) the efficacy of PEG-IFNα-2a + ribavirin administered for 24 or 48 weeks. It will be evaluated whether 48 weeks of therapy may achieve better results compared to the standard duration (24 weeks).

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: pegylated interferon alpha 2a + ribavirin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2012
Estimated Primary Completion Date : November 2015
Estimated Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Control Arm 24 weeks
PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
Drug: pegylated interferon alpha 2a + ribavirin
Comparison of different duration of drugs (48 weeks vs. 24 weeks)

Experimental: Active arm (48 weeks)
PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
Drug: pegylated interferon alpha 2a + ribavirin
Comparison of different duration of drugs (48 weeks vs. 24 weeks)

Primary Outcome Measures :
  1. Sustained virological response (SVR) [ Time Frame: 6 months after therapy withdrawal ]
    HCV-RNA undetectability (by the means of Real time PCR assay with a sensitivity limit of 20 UI/mL) 6 months after therapy withdrawal.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent
  • Age more than 18 years
  • Compensated liver disease with following pre-enrollment hematological parameters: Hemoglobin more than 13 g/dl in males and 12 g/dl in females; White blood cell count more than 3,000/mmc; Platelet count more than 100,000 /mmc
  • Anti-nuclear antibodies (ANA) less than 1:160
  • Anti-Liver-Kidney antibodies (LKM1): negative
  • alpha1 fetoprotein levels less than 50 ng/ml in 3 months before enrollment and liver Ultrasound negative for focal malignant lesions.
  • HBsAg: negative
  • Clinical or histological diagnosis of chronic hepatitis C
  • HCV-RNA: positive
  • Relapse (end-of-treatment HCV-RNA negativity and positivization within 6 months after therapy withdrawal) to at-least one previous treatment of PEG-IFN (alpha2a or alpha2b) + ribavirin which should have lasted at least for 80% of the 24 planned weeks with at least 80% of total planned dose of PEG-IFN and ribavirin administered.
  • Normal values of total and direct bilirubin (with the exception of indirect bilirubin due to extrahepatic factors such as Gilbert syndrome; in these cases the levels should be less than 3 mg/dL).
  • Normal values of albumin and creatinin
  • Normal fasting glycemia or, in case of glycemic values between 115mg/dL and 140 mg/dl (values confirmed in more than one determination) or if the patient is affected by diabetes mellitus, glycated hemoglobin should be < 8,5%.
  • Normal Thyroid Stimulating Hormone (TSH) level. Subjects under pharmacological treatment to maintain normal TSH levels can be enrolled if they fulfill other criteria.
  • In case of history of diabetes or hypertension a specialist examination is required to rule out contraindication to therapy.
  • Adoption of contraceptive measures

Exclusion Criteria:

  • Age less than 18 years
  • Women during pregnancy or breast-feeding
  • Previous treatment with PEG-IFN alpha2a or alpha2b + ribavirin for more than 6 months
  • Participation to any clinical trial within 30 days from enrollment in this protocol
  • Subjects with solid organ transplantation (with the exception of cornea or hair transplantation)
  • Subject not willing to have a counseling or to abstain from alcohol use
  • Suspected hypersensitivity to PEG-Interferon alpha2a or ribavirin
  • Any other cause of liver disease different from chronic hepatitis C based on anamnesis of patient or on histological evidence including but not limited to:
  • HBV coinfection
  • Alpha-1 antitrypsin deficiency
  • Wilson disease
  • Autoimmune hepatitis
  • Alcoholic liver disease
  • Hemoglobinopathy included but not limited to thalassemia major.
  • Advanced liver diseases diagnosed through history or presence of ascites, esophageal variceal bleeding or hepatic encephalopathy
  • Psychiatric conditions: depression or medical history of severe psychiatric alterations such as major psychosis, suicidal ideas, suicidal attempts, depression that required hospitalization or electroconvulsive therapy, prolonged work leave or significant impairment of everyday activities should be excluded. Subjects with history of slight depression might be considered for enrollment in the study if a pre-treatment psychiatric evaluation indicates that the subject is stable and that is possible to follow its mental status during the study.
  • Central nervous system trauma or convulsive status requiring treatment.
  • Cardiovascular diseases (e.g. angina, congestive heart disease, myocardial infarction, major arrhythmias).
  • Decompensated diabetes mellitus
  • Clinical gout
  • Chronic pulmonary diseases
  • Immune-mediated diseases (e.g. chronic inflammatory bowel diseases, idiopathic thrombocytopenic purpura, Systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)
  • Abuse of substances such as alcohol (more than 80 g/die), i.v. or inhalator drugs. Subjects with a history of drug abuse can be enrolled if they were abstinent for at least 2 years.
  • Subjects with clinically relevant retinal lesions
  • Any other condition that at investigators opinion could be a reason of non suitability for patients or can interfere with his/her participation to the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01517308

Layout table for location information
University of Naples Federico II
Naples, Italy, I-80131
Sponsors and Collaborators
Federico II University
Layout table for investigator information
Principal Investigator: Guglielmo Borgia, Professor Federico II University

Layout table for additonal information
Responsible Party: Prof. Guglielmo Borgia, Full Professor, Federico II University Identifier: NCT01517308     History of Changes
Other Study ID Numbers: C.E. Federico II 47/11
First Posted: January 25, 2012    Key Record Dates
Last Update Posted: March 19, 2012
Last Verified: March 2012
Keywords provided by Prof. Guglielmo Borgia, Federico II University:
Genotype 2 or 3
Pegylated Interferon
Additional relevant MeSH terms:
Layout table for MeSH terms
Interferon alpha-2
Peginterferon alfa-2a
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs